Page 302 - Williams Hematology ( PDFDrive )

276 Part IV: Molecular and Cellular Hematology Chapter 18: Hematopoietic Stem Cells, Progenitors, and Cytokines 277

313. Namen AE, Lupton S, Hjerrild K, et al: Stimulation of B-cell progenitors by cloned 329. Hodohara K, Fujii N, Yamamoto N, et al: Stromal cell-derived factor-1 (SDF-1) acts
murine interleukin-7. Nature 333:571, 1988. together with thrombopoietin to enhance the development of megakaryocytic progen-
314. Gibson LF, Piktel D, Landreth KS: Insulin-like growth factor-1 potentiates expansion of itor cells (CFU-MK). Blood 95:769, 2000.
interleukin-7-dependent pro-B cells. Blood 82:3005, 1993. 330. Sawada K, Krantz SB, Dai CH, et al: Purification of human blood burst-forming units-
315. Nagasawa T, Kikutani H, Kishimoto T: Molecular cloning and structure of a pre-B-cell erythroid and demonstration of the evolution of erythropoietin receptors. J Cell Physiol
growth-stimulating factor. Proc Natl Acad Sci U S A 91:2305, 1994. 142:219, 1990.
316. McNiece IK, Langley KE, Zsebo KM: The role of recombinant stem cell factor in early 331. Sporn LA, Chavin SI, Marder VJ, et al: Biosynthesis of von Willebrand protein by
B cell development. Synergistic interaction with IL-7. J Immunol 146:3785, 1991. human megakaryocytes. J Clin Invest 76:1102, 1985.
317. Gongora R, Stephan RP, Zhang Z, et al: An essential role for Daxx in the inhibition of B 332. Pevny L, Simon MC, Robertson E, et al: Erythroid differentiation in chimaeric mice
lymphopoiesis by type I interferons. Immunity 14:727, 2001. blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature
318. Yoshikawa H, Nakajima Y, Tasaka K: IFN-gamma induces the apoptosis of WEHI 279 349:257, 1991.
and normal pre-B cell lines by expressing direct inhibitor of apoptosis protein binding 333. Shivdasani RA, Fujiwara Y, McDevitt MA, et al: A lineage-selective knockout estab-
protein with low pI. J Immunol 167:2487, 2001. lishes the critical role of transcription factor GATA-1 in megakaryocyte growth and
319. Mitchell PL, Clutterbuck RD, Powles RL, et al: Interleukin-4 enhances the survival of platelet development. EMBO J 16:3965, 1997.
severe combined immunodeficient mice engrafted with human B-cell precursor leuke- 334. Tsang AP, Visvader JE, Turner CA, et al: FOG, a multitype zinc finger protein, acts as a
mia. Blood 87:4797, 1996. cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentia-
320. Lee G, Namen AE, Gillis S, et al: Normal B cell precursors responsive to recombinant tion. Cell 90:109, 1997.
murine IL-7 and inhibition of IL-7 activity by transforming growth factor-beta. J Immunol 335. Nichols KE, Crispino JD, Poncz M, et al: Familial dyserythropoietic anaemia and
142:3875, 1989. thrombocytopenia due to an inherited mutation in GATA1. Nat Genet 24:266, 2000.
321. Bain G, Maandag EC, Izon DJ, et al: E2A proteins are required for proper B cell devel- 336. Doubeikovski A, Uzan G, Doubeikovski Z, et al: Thrombopoietin-induced expression
opment and initiation of immunoglobulin gene rearrangements. Cell 79:885, 1994. of the glycoprotein IIb gene involves the transcription factor PU.1/Spi-1 in UT7-Mpl
322. Bain G, Robanus Maandag EC, te Riele HP, et al: Both E12 and E47 allow commitment cells. J Biol Chem 272:24300, 1997.
to the B cell lineage. Immunity 6:145, 1997. 337. Athanasiou M, Clausen PA, Mavrothalassitis GJ, et al: Increased expression of the
323. Kee BL, Quong MW, Murre C: E2A proteins: Essential regulators at multiple stages of ETS-related transcription factor FLI-1/ERGB correlates with and can induce the
B-cell development. Immunol Rev 175:138, 2000. megakaryocytic phenotype. Cell Growth Differ 7:1525, 1996.
324. Iscove NN, Sieber F: Erythroid progenitors in mouse bone marrow detected by macro- 338. Giles F, Estey E, O’Brien S: Gemtuzumab ozogamicin in the treatment of acute myeloid
scopic colony formation in culture. Exp Hematol 3:32, 1975. leukemia. Cancer 98:2095, 2003.
325. Clarke BJ, Housman D: Characterization of an erythroid precursor cell of high prolif- 339. Pagano L, Fianchi L, Caira M, Rutella S, Leone G: The role of gemtuzumab ozogamicin
erative capacity in normal human peripheral blood. Proc Natl Acad Sci U S A 74:1105, in the treatment of acute myeloid leukemia patients. Oncogene 26:3679, 2007.
1977. 340. Stasi R: Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment
326. Long MW, Heffner CH, Williams JL, et al: Regulation of megakaryocyte phenotype in of acute myeloid leukaemia. Expert Opin Biol Ther 8:527, 2008.
human erythroleukemia cells. J Clin Invest 85:1072, 1990. 341. Khanna-Gupta A, Zibello T, Sun H, et al: C/EBP epsilon mediates myeloid differenti-
327. McDonald TP, Sullivan PS: Megakaryocytic and erythrocytic cell lines share a common ation and is regulated by the CCAAT displacement protein (CDP/cut). Proc Natl Acad
precursor cell. Exp Hematol 21:1316, 1993. Sci U S A 98:8000, 2001.
328. Nakahata T, Okumura N: Cell surface antigen expression in human erythroid progeni- 342. Dahl R, Walsh JC, Lancki D, et al: Regulation of macrophage and neutrophil cell fates
tors: Erythroid and megakaryocytic markers. Leuk Lymphoma 13:401, 1994. by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat Immunol
4:1029, 2003.

Kaushansky_chapter 18_p0257-0278.indd 277 9/19/15 12:06 AM